Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of XNW28012 versus placebo plus best supportive care in previously treated metastatic pancreatic cancer
CTR20252545Phase 3Active
- Sponsor
- Sinovent
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of xnw28012 in pancreatic adenocarcinoma (PDAC), pancreatic adenosquamous carcinoma (PASC), sponsored by Sinovent. Started Jul 2025; status: active.
02
Drugs
xnw28012
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic adenosquamous carcinoma (PASC)
Beyond the preview
Go deeper on CTR20252545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252545.